A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19539845.
- Also identified by DOI 10.1016/j.jaad.2008.11.889.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Long-term prognosis for advanced stages of cutaneous T-cell lymphoma may be beneficially altered with the use of multimodality therapy. However, refractory disease exists in which current therapeutic options fail to halt the progression of disease. We present 3 cases of refractory Sézary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. The potential immunologic basis for this is discussed.
Medical subject headings
- Hydroxamic Acids
- Interferon-gamma
- Sezary Syndrome